159 related articles for article (PubMed ID: 22644023)
1. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571.
Leeds JA; Sachdeva M; Mullin S; Dzink-Fox J; Lamarche MJ
Antimicrob Agents Chemother; 2012 Aug; 56(8):4463-5. PubMed ID: 22644023
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
Trzasko A; Leeds JA; Praestgaard J; Lamarche MJ; McKenney D
Antimicrob Agents Chemother; 2012 Aug; 56(8):4459-62. PubMed ID: 22644020
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
[TBL] [Abstract][Full Text] [Related]
5. Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.
Leeds JA
Cold Spring Harb Perspect Med; 2016 Feb; 6(2):a025445. PubMed ID: 26834162
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolone resistance and Clostridium difficile, Germany.
Zaiss NH; Witte W; Nübel U
Emerg Infect Dis; 2010 Apr; 16(4):675-7. PubMed ID: 20350385
[TBL] [Abstract][Full Text] [Related]
7. Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile.
Sachdeva M; Leeds JA
Antimicrob Agents Chemother; 2015 Feb; 59(2):1252-7. PubMed ID: 25512411
[TBL] [Abstract][Full Text] [Related]
8. In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.
Carman RJ; Boone JH; Grover H; Wickham KN; Chen L
Antimicrob Agents Chemother; 2012 Nov; 56(11):6019-20. PubMed ID: 22908175
[TBL] [Abstract][Full Text] [Related]
9. In vivo selection of moxifloxacin-resistant Clostridium difficile.
Mena A; Riera E; López-Causapé C; Weber I; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2012 May; 56(5):2788-9. PubMed ID: 22371889
[No Abstract] [Full Text] [Related]
10. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
Leeds JA; Sachdeva M; Mullin S; Barnes SW; Ruzin A
J Antimicrob Chemother; 2014 Jan; 69(1):41-4. PubMed ID: 23887866
[TBL] [Abstract][Full Text] [Related]
11. Discovery of LFF571: an investigational agent for Clostridium difficile infection.
LaMarche MJ; Leeds JA; Amaral A; Brewer JT; Bushell SM; Deng G; Dewhurst JM; Ding J; Dzink-Fox J; Gamber G; Jain A; Lee K; Lee L; Lister T; McKenney D; Mullin S; Osborne C; Palestrant D; Patane MA; Rann EM; Sachdeva M; Shao J; Tiamfook S; Trzasko A; Whitehead L; Yifru A; Yu D; Yan W; Zhu Q
J Med Chem; 2012 Mar; 55(5):2376-87. PubMed ID: 22315981
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
[TBL] [Abstract][Full Text] [Related]
13. Multidisciplinary analysis of a nontoxigenic Clostridium difficile strain with stable resistance to metronidazole.
Moura I; Monot M; Tani C; Spigaglia P; Barbanti F; Norais N; Dupuy B; Bouza E; Mastrantonio P
Antimicrob Agents Chemother; 2014 Aug; 58(8):4957-60. PubMed ID: 24913157
[TBL] [Abstract][Full Text] [Related]
14. The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity.
Kang JK; Hwang JS; Nam HJ; Ahn KJ; Seok H; Kim SK; Yun EY; Pothoulakis C; Lamont JT; Kim H
Antimicrob Agents Chemother; 2011 Oct; 55(10):4850-7. PubMed ID: 21807975
[TBL] [Abstract][Full Text] [Related]
15. A high-throughput small-molecule screen to identify a novel chemical inhibitor of Clostridium difficile.
Katzianer DS; Yano T; Rubin H; Zhu J
Int J Antimicrob Agents; 2014 Jul; 44(1):69-73. PubMed ID: 24837414
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of linezolid against Clostridium difficile.
Peláez T; Alonso R; Pérez C; Alcalá L; Cuevas O; Bouza E
Antimicrob Agents Chemother; 2002 May; 46(5):1617-8. PubMed ID: 11959617
[TBL] [Abstract][Full Text] [Related]
17. Surface layer protein A variant of Clostridium difficile PCR-ribotype 027.
Spigaglia P; Barbanti F; Mastrantonio P
Emerg Infect Dis; 2011 Feb; 17(2):317-9. PubMed ID: 21291621
[No Abstract] [Full Text] [Related]
18. Improving the reproducibility of the NAP1/B1/027 epidemic strain R20291 in the hamster model of infection.
Kelly ML; Ng YK; Cartman ST; Collery MM; Cockayne A; Minton NP
Anaerobe; 2016 Jun; 39():51-3. PubMed ID: 26946361
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
Karlowsky JA; Laing NM; Zhanel GG
Antimicrob Agents Chemother; 2008 Nov; 52(11):4163-5. PubMed ID: 18725442
[TBL] [Abstract][Full Text] [Related]
20. Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile.
Babakhani F; Seddon J; Robert N; Shue YK; Sears P
Antimicrob Agents Chemother; 2010 Jun; 54(6):2674-6. PubMed ID: 20308366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
